Pfizer Inc. announced last week that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. The treatment includes nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer's laboratories, which was specifically designed to block the activity of the SARS-CoV-2 Mpro, an enzyme that the coronavirus needs to replicate.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
29.96 USD | +1.54% | +5.63% | +4.01% |
08:31pm | Mark Cuban's Cost Plus to import penicillin to address US shortage | RE |
10:20am | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.92% | 167B | |
+56.16% | 848B | |
+31.64% | 627B | |
-0.21% | 363B | |
+15.26% | 318B | |
+12.94% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.26% | 179B | |
+2.52% | 125B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Pfizer Inc. Announces U.S. Food and Drug Administration Authorized Emergency Use of PAXLOVID